This week saw a long-awaited FDA approval for a Boston-area drug maker, speculation about a possible buyout of a local biotech giant, and some in-depth profiles on other key life sciences players.

—Hospital software maker Picis, of Wakefield, MA, said it is being acquired by Ingenix, an Eden Prairie, MN-based healthcare intelligence and analytics firm. The companies didn’t disclose financials details of the transaction, but Ingenix said it will maintain Picis’ locations in Wakefield and throughout the U.S. and Europe.

—Cambridge, MA-based Momenta Pharmaceuticals nabbed a long-sought FDA approval for a generic version of the anti-clotting drug it developed with Novartis unit Sandoz. The regulatory approval proves that Momenta (NASDAQ: MNTA) can make equivalents of more complex drug mixtures, which pose a greater challenge for would-be generics makers than do more conventional small-molecule pills, Luke wrote.

Ingenix is a has-been in todays’s medical field. The work in a loft over most people’s heads trying to rule the roost of “misunderstanding”. Ryan (puppet), Laurie (butch), and Christine (who dresses like a hillbilly whore during the summer) make life their very obfuscated. I’m trying to get a new job, but there aren’t any, and I’m stuck in misery. I need to get out of this company!!!!!!!